A phase II multi-center clinical trial to study the efficacy and in vivo trafficking of autologous adoptively transferred ex vivo expanded regulatory T cells in patients with ulcerative colitis (C04)

• Subject Area: Gastroenterology ; Immunology
• Term: since 2018
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 375876048

We have developed an authority-approved method to generate suppressive regulatory T cells (Tregs) and currently perform a dose-finding study in patients with ulcerative colitis. After finding the maximal tolerable dose, we continue to test the efficacy and in vivo trafficking of these Tregs in a multi-center phase II study. In addition, we will perform studies to define the interactions of the Tregs with effector T cells and the gut mucosa and plan to develop Tregs expressing an optimized molecular signature to further increase homing to the gut.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 241: Immune-Epithelial Communication in Inflammatory Bowel Diseases
• Applicant Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
• Project Heads: Professorin Caroline Bosch-Voskens, Ph.D.; Professor Dr. Markus F. Neurath